Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials-MedSci.cn

Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

O'Malley, DM; Oaknin, A; Monk, BJ; Leary, A; Selle, F; Alexandre, J; Randall, LM; Rojas, C; Neffa, M; Kryzhanivska, A; Gladieff, L; Berton, D; Meniawy, T; Lugowska, I; Bondarenko, I; Moore, KN; Feliu, WIO; Ancukiewicz, M; Shapiro, I; Ray-Coquard, IL

ANNALS OF ONCOLOGY, 2020; 31 (): S1164

科室
- - 订阅+
  - 更多科室
工具
服务